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Abstract
Previous investigations of p150,95 (CD11c), the third member
of the CD18 membrane glycoprotein family that includes CR3
(Mac-i or CD11b) and LFA-1 (CD11a), had demonstrated
that solubilized p150,95 bound to iC3b-agarose in a manner
similar to isolated CR3. The current study showed that mem-
brane surface p150,95 also expressed iC3b-receptor activity
and was probably the same as the neutrophil receptor for iC3b-
or C3dg-coated erythrocytes (EC3bi or EC3dg) that had been
previously designated CR4. Normal neutrophil and macro-
phage CR4-dependent EC3bi rosettes were inhibited by mono-
clonal anti-pl5,95, and cells from a patient with CD18 defi-
ciency did not form CR4-dependent EC3bi rosettes. With neu-
trophils that bore large amounts of CRI and CR3 and little
p150,95, EC3bi were bound primarily via CRI and CR3, and
demonstration of p150,95-dependent rosettes required large
amounts of fixed iC3b, low-ionic strength buffer, and antibody
blockade of CR1 and CR3. By contrast, culture-derived macro-
phages expressed eight times more p150,95 than did mono-
cytes and EC3bi were bound to both p150,95 and CR3 when
EC3bi bore small amounts of fixed iC3b and assays were car-
ried out in isotonic buffer. Comparison of the amounts of CRI,
CR3, and CR4 in various tissues by immunoperoxidase staining
revealed that CR4 was the most abundant C3 receptor molecule
on tissue macrophages, and suggested that CR4 might be in-
volved in clearance of C3-opsonized particles or immune com-
plexes.
Introduction
The membrane glycoprotein p 150,95 (CDlIc; 150 kD a-chain
linked noncovalently to 95 kD p3-chain) is expressed on phago-
cytic cells, natural killer (NK)' cells, and certain cytotoxic T
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1. Abbreviations used in this paper: BDVA, low-ionic strength rosetting
buffer consisting of 1% bovine serum albumin (BSA)/3.2% dextrose/
3.5 mM veronal buffer pH 7.2/10 mM sodium chloride/10 mM so-
cells (1-3). The 95 kD (i-chain (CD18) is structurally identical
to the ,B-chains of two other related leukocyte membrane gly-
coproteins, LFA-l (lymphocyte function-associated antigen 1
or CDl la) and CR3 (complement receptor type 3, Mac-l, or
CDl lb) that have structurally distinct a-chains of 175 and 165
kD, respectively (4). Much interest has focused on this family
of three surface glycoproteins ("CD18 complex") with the
identification of several patients who have an inherited defi-
ciency of the entire CD18 complex and suffer from recurrent
bacterial infections (4-6). Recently, nucleotide sequence anal-
ysis has indicated that the three members of the CD18 com-
plex are members of a larger supergene family of seven other
membrane glycoproteins that includes the five VLA glycopro-
teins, the vitronectin receptor and platelet glycoprotein
GPIIb/IIIa (7-9). All ten of these glycoproteins are either re-
ceptors or have adhesion-related functions, and several of the
ligands for the receptors that have been characterized are
bound via a similar Arg-Gly-Asp (RGD) tripeptide structure
(10). Among CD18 family members, CR3 has been shown to
recognize an RGD peptide within iC3b (1 1).
The functions of p 150,95 are just beginning to be defined.
Examination ofCD1 8-deficient neutrophils or normal neutro-
phils treated with antibodies specific for individual a- or #-
chains suggests that both CR3 and p150,95 have common
functions in mediating neutrophil and monocyte adherence to
protein-coated glass (12) and endothelial cells (13, 14). Fur-
thermore, the adherence step involved in conjugate formation
between cytotoxic T cells and target cells has recently been
shown to be inhibitable by antibodies to the a-chain of
p1 50,95 (15) as well as by antibodies to the a-chain of LFA- 1
(16) or the common a-chain (15, 16). With neutrophils and
freshly isolated monocytes that express large amounts of CR3
and small amounts of p150,95 and LFA-1, CR3 has been
shown to be the major receptor for fixed iC3b (17, 18-20).
Recently, however, detergent solubilized p150,95 from U937
cells was shown either to coelute with CR3 from iC3b-agarose
affinity columns (21), or to be purified on iC3b-agarose after
selective removal of CR3 by immunoprecipitation (22), sug-
gesting that it might function as an iC3b-receptor analogous to
CR3. Up until this time, however, attempts to demonstrate
dium azide/2 mM each of calcium chloride and magnesium chloride,
4.5 mS conductivity at 22°C; CD18, the common (i-chain shared by
each of the three members of CDI la/CDl lb/CDl lc membrane gly-
coprotein family consisting ofLFA- I (lymphocyte function-associated
antigen 1 or CDl la), CR3 (complement receptor type three, same as
Mac-l or CDl lb, specific for iC3b), and CR4 (complement receptor
type four, same as p150,95, Leu M5, or CDl lc, specific for iC3b);
CR,, complement receptor type one (specific for C3b, C4b, and iC3b);
HBSS/BSA, Hanks' balanced salt solution containing 1% BSA; MAb,
monoclonal antibody; NK cells, natural killer cells.
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anti-p 1 50,95 inhibitable iC3b-receptor activity on intact cells
had been unsuccessful (2, 22).
In the current study, a receptor for fixed iC3b on sheep
erythrocytes (EC3bi) was demonstrated on neutrophils and
monocyte-derived macrophages that was not inhibited by a
polyclonal mixture of anti-CR1 and anti-CR3 antibodies. This
receptor activity on neutrophils appears to be the same as the
receptor for EC3bi and EC3dg rosettes that had been pre-
viously designated CR4 (23). CR4 activity was weak and vari-
able on neutrophils and freshly isolated monocytes, and
seemed to correspond to low levels of p150,95 expression. By
contrast, macrophages generated by 7-d culture of monocytes
expressed avid CR4 rosetting activity and large amounts of
p150,95. With both cell types, CR4 rosetting activity was inhib-
ited by antibodies to the a-chain of p150,95, suggesting that
cell surface p150,95 is probably identical to CR4.
Methods
Neutrophils and monocytes. Blood was obtained from normal volun-
teers or a patient with inherited deficiency ofLFA- I/CR3/pl 50,95 (5).
Mononuclear cells were isolated by dextran sedimentation and Ficoll-
Hypaque centrifugation (24), and cultured for 7 d, either as nonadher-
ent cells in Teflon beakers (25), or as adherent cells in either 24-well
plates (24, 26) or 4-well Lab-Tek slide chambers (Miles Scientific,
Naperville, IL). For the slide chambers, 2 X 106 mononuclear cells
were added to each well. Cells cultured for 7 d in Teflon beakers were
transferred to slide chambers coated with either mouse myeloma IgG
or monoclonal antibodies (MAbs) (19, 25). Lymphocytes were re-
moved by this adherence step. Neutrophils were prepared either from
the Ficoll-Hypaque pellet generated during monocyte isolation (using
ammonium chloride for lysis of erythrocytes), or by two-step Ficoll-
Hypaque gradients (17). Neutrophils were tested either in suspension
or after allowing adherence for 1 h to 8-well slide chambers (5 X 105
neutrophils/well in 200 Ml of Hanks' balanced salt solution containing
1% bovine serum albumin; HBSS/BSA).
Antibodies. Rabbit F(ab')2 anti-CR1 was used to block CR1 rosettes
(27), and El1 MAb anti-CR1 was used to quantitate CR1 expression
(28). MAbs to CR3 a-chain included MN-41 (20, 29), from Dr. Alfred
Michael and Dr. Allison Eddy (University of Minnesota, Minneapo-
lis), anti-Mac-1 (18), hybridoma provided by Dr. Timothy Springer
(Dana-Farber Cancer Institute, Boston, MA), anti-Mo 1 (30), from Dr.
Robert Todd (University of Michigan, Ann Arbor), and the IgG, MAb
44 (22). MAbs to p 150,95 a-chain included anti-Leu M5 (2) and L29
from Dr. Lewis Lanier of Becton Dickinson Monoclonal Center
(Mountain View, CA), and the IgG, mAb 3.9 (31). L29 is an IgGI MAb
that was generated by immunization of Balb/c mice with human pe-
ripheral blood lymphocytes enriched for NK cells by Percoll density
gradient centrifugation (32). Immune splenocytes were fused with
SP2/0 Ag14 myeloma cells, and hybridomas were selected in azaserine.
L29 has been designated as CDl lc reactive (33) on the following basis:
(a) identical size a- and a-chains precipitated by L29 and anti-Leu M5,
(b) identical immunofluorescence flow cytometry histogram as anti-
Leu M5 with neutrophils and mononuclear cells, (c) absent fluores-
cence staining of cells from two patients with inherited deficiency of
LFA-l/CR3/pl50,95, (d) inhibition of EC3bi rosettes in a manner
similar to both anti-Leu M5 and 3.9. The epitope specificity of anti-
p 150,95 MAbs was evaluated by cross-blocking experiments in which
one MAb labeled with 1251I was tested for uptake onto neutrophils or
U937 cells that had been incubated with a 100-fold molar excess of
unlabeled homologous or nonhomologous MAb (34). Control nonspe-
cific myeloma proteins included IgG, MOPC-21 (Litton Bionetics,
Charleston, SC) and IgG2. P1.17 (myeloma line obtained from the
American Type Culture Collection, Rockville, MD). The murine hy-
bridoma ATCC HB-120 (BB7.5) secreting IgGI specific for MHC class
I antigens (HLA-A, B, C) was kindly provided by Dr. Jeffrey Frelinger,
University of North Carolina at Chapel Hill (35). Each monoclonal
immunoglobulin (except for those received as IgG) was purified from
ascites fluid or culture supernatant by high performance liquid chro-
matography using cation exchange (Protein Pak SP-5PW; Waters As-
sociates, Milford, MA) with 10 mM sodium acetate pH 5.5 and a
sodium chloride gradient, followed by anion exchange (Protein Pak
DEAE-5PW; Waters Associates) with 20 mM Tris/HCl pH 8.5 and a
sodium chloride gradient (36).
Preparation ofEC3. EC3b and EC3bi were prepared as previously
described, followed by analysis of bound C3 fragments with '25I-la-
beled MAbs to C3c, C3g, and C3d (17). For assays of neutrophils and
monocytes, EC3bi with 4.5-6.5 X 104 molecules of iC3b/E were used.
With monocyte-derived macrophages, EC3bi with 1.2-1.8 X I04 mole-
cules of iC3b/E were used.
EC3 rosette assay. Neutrophils in suspension were tested for ro-
settes as before (17). Adherent neutrophils or monocytes in 8-well slide
chambers were washed three times and reconstituted with 140 Ml/well
of low-ionic strength BDVA buffer (1% BSA/3.2% dextrose/3.5 mM
veronal buffer/10 mM sodium chloride-/10 mM sodium azide/2 mM
each of calcium chloride and magnesium chloride, pH 7.2, 4.5 mS at
22°C). With macrophages in 4-well chambers, 225 Al of isotonic
HBSS/BSA was used instead of BDVA. Next, 100 ul of EC3bi (2
X 108/ml in BDVA or HBSS/BSA) was added to each well, and after 15
min at 37°C, the wells were washed to remove unbound EC3bi, the
partitioned top chamber was removed, and a 50 X 22 mm coverslip
was placed over the adherent cells on the glass slide. Rosettes were
observed by phase contrast microscopy with cells bearing 2 4 bound
EC3bi scored as positive. Neutrophil assays included 1 mg/ml of soy-
bean trypsin inhibitor (Sigma Chemical Co., St. Louis, MO) to prevent
elastase proteolysis of iC3b on the EC3bi (37).
For studies of antibody blockade of rosettes, adherent phagocytes
were incubated for 20 min with antibodies, the volume was brought up
to 140 ,ul (8-well chambers) or 225 Ml (4-well chambers) with buffer,
and 100,l ofEC3bi were added for rosette assay without washing away
unbound antibodies. With neutrophils in suspension, assays were also
carried out with excess fluid phase antibodies (20). The amount of
F(ab')2 anti-CR, used was sufficient to block all monocyte and neutro-
phil rosettes with EC3b (17). To determine the appropriate amount of
each anti-CR3 MAb, titrations for inhibition of rosette formation were
carried out with each phagocytic cell type (results shown for adherent
neutrophils only, Fig. 1). For subsequent assays ofCR4 rosetting activ-
ity, amounts of anti-CR3 MAbs were used that were 4- to 10-fold
greater than the amounts producing maximum plateau levels ofinhibi-
tion of EC3bi rosette formation in the presence or absence of excess
rabbit F(ab')2 anti-CR1 . As an alternative procedure for demonstration
ofpl 50,95-dependent rosettes, surface p1 50,95 on monocytes cultured
for 7 d in Teflon beakers was modulated from the apical surfaces of
cells by 45 min cultivation in slide chambers coated with monoclonal
anti-pl50,95 attached via poly L-lysine and glutaraldehyde (19, 25).
Surfaces coated with MAb anti-CR3, anti-MHC class I, or myeloma
IgG served as controls. MAbs to CR3 and/or p1 50,95 were then added
in the fluid phase prior to EC3bi addition.
Quantitation ofCR,, CR3, andp150,95. Neutrophils were tested in
suspension for uptake of '251I-MAbs (34). Serial dilutions of '251-MAbs
were tested, and the number ofantigen sites per cell was determined by
Scatchard analysis using the Ligand program (Biomedical Computing
Technology Information Centre, Nashville, TN). Monocytes cultured
in 24-well plates were examined for uptake of '25I-MAbs within 2 h
after adherence and again after cultivation for 7 d. The number of
adherent cells per well at the time of assay was determined by Coulter
counting of nuclei released with Zapoglobin (Coulter Electronics, Hia-
leah, FL) from triplicate wells incubated with buffer instead of 121I_
MAb. The amount of '251-MAb bound in the presence of a 100-fold
molar excess of homologous unlabeled MAb was subtracted from the
total amount of bound '251-MAb to determine the amount of specifi-
cally bound '25I-MAb. With each mAb (E 1, MN-41, and 3.9) titration
studies showed that 400 ng of '251-MAb in 300 Mil of HBSS/BSA was
saturating. Cells were first incubated with either unlabeled MAb or
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Figure 1. Titration of anti-CR3 MAbs for inhibition of adherent neu-
trophil EC3bi rosette formation. The results plotted are the mean of
three assays of adherent neutrophils with EC3bi bearing 5.7 X 104
iC3b/E in BDVA low-ionic strength buffer. Neutrophils adhered to
eight-well slide chambers (- 4 X 104 adherent neutrophils per
chamber) were treated with F(ab')2 anti-CR1 (140 ,g) plus the
amount of each MAb listed in a total volume of 150 Ml for 20 min
before addition of 100 Al of EC3bi for assay of rosette formation. A
mixture of 4 ,g each of MN-41 and anti-Mol (solid square) was com-
pared to the same mixture containing 8 1g of anti-Mac-l (solid trian-
gle). Similar results were obtained with each of the other phagocyte
types (not shown), and thus the amounts of each anti-CR3 MAb used
in the experiments shown in Tables I-IV were sufficient to produce
plateau levels of inhibition of CR3 rosetting activity.
buffer for 20 min at 40C, and then incubated with '251-labeled MAb for
20 min at 40C. After four washes with HBSS/BSA, cells with bound
1251I-MAb were eluted for gamma scintillation counting with I ml of
0.05% Triton X-100, 1 ml of HBSS/BSA, and vigorous pipetting.
Immunoperoxidase labeling ofmonocytes and tissue sections. The
following fresh-frozen tissues were obtained from the Imperial Cancer
Research Fund Department of Histopathology: tonsil, spleen, thymus,
lung, skin, brain, bronchus, and colon. All tissues were judged to be
normal by histopathologists, with the exception of reactive tonsils,
which were removed after antibiotic therapy of patients. All tissues
were obtained from adults except tonsil and thymus obtained from
children. Glass-adherent monocytes and 6 Mm sections of acetone-
fixed fresh-frozen tissues were subjected to indirect immunoperoxidase
staining with MAbs as previously reported (28, 31). Briefly, samples
were incubated at room temperature for 30 min with 50 Ml of various
IgG, MAb-containing supernatants, followed, after appropriate wash-
ing by 40 MAl ofperoxidase-conjugated goat antimouse immunoglobulin
(1:100; Dakopatts, Copenhagen, Denmark). A positive reaction was
revealed by a 7-min exposure to hydrogen peroxide (0.0 12%) and
3,3'-diaminobenzidene (0.6 mg/ml). Controls for the IgG1 MAbs El 1,
44 and 3.9 were a nonspecific IgG, MAb and omission of first layer
antibodies.
Results
Expression ofCR4-dependent rosettes. CR4-dependent rosettes
were defined as EC3bi rosettes with neutrophils or monocytes
that had been treated with amounts of anti-CR1 and anti-CR3
that were sufficient to inhibit CRI- and CR3-dependent ro-
settes completely. With neutrophils, such CR4-dependent ro-
settes had been previously shown (23) to require > 45,000
molecules of iC3b or C3dg per EC3bi or EC3dg and a low-
ionic strength buffer (BDVA). When neutrophils were exam-
ined for such CR4-dependent rosettes in the present study, it
was found that some of the rosettes formed in the presence of
rabbit anti-CR, and saturating amounts of MN-41 anti-CR3
could be blocked by further treatment of cells with saturating
amounts of a second and/or third anti-CR3 MAb such as anti-
Mol and/or anti-Mac-l (Fig. 1). For this reason, subsequent
tests of putative CR4-dependent rosettes were carried out with
a mixture of rabbit anti-CR1 and three anti-CR3 MAbs
(MN-4 1, anti-Mac- 1, anti-Mo 1). When tested in this way, neu-
trophils from 6 of 14 donors formed . 15% CR4-dependent
rosettes, i.e., nearly all rosettes were abolished by the anti-
CR I/CR3 mixture. The results given in Table I are for the eight
remaining neutrophil preparations giving . 23% CR4-depen-
dent rosettes, as only these preparations were judged satisfac-
tory for tests for inhibition of rosettes by anti-p 150,95.
Freshly isolated monocytes tested on four occasions
formed only 6-14% CR4-dependent rosettes and so were not
examined further. By contrast, macrophages generated by cul-
tivation of adherent monocytes for 7 d formed much higher
proportions of CR4-dependent rosettes, even when EC3bi
contained as few as 12,000 iC3b per E and assays were carried
in isotonic buffer (Table II).
Both CR3 and CR4 had similar requirements for divalent
cations, because all EC3bi rosettes formed with adherent mac-
rophages were blocked by anti-CR1 in either HBSS/BSA or
BDVA containing 20 mM EDTA (data not shown).
Inhibition of CR4-dependent EC3bi rosettes with anti-
p150,95. Each of three available MAbs to the a-chain of
p150,95 was found to be specific for a distinct epitope of
p 150,95, as uptake of each 125I-labeled MAb by neutrophils or
U937 cells was blocked only by the unlabeled homologous
MAb (data not shown). Each ofthe anti-p150,95 MAbs inhib-
ited CR4-dependent EC3bi rosettes with neutrophils and
monocyte-derived macrophages (Tables I and II). With neu-
trophils in suspension, significant inhibition required a mix-
ture of two or three anti-p 1 50,95 MAbs. However, inhibition
of adherent neutrophil CR4-dependent rosettes was demon-
strated with each of the IgGI anti-p 150,95 MAbs individually.
By contrast, substitution ofan IgG1 anti-class I MAb for one of
the IgG, anti-pI50,95 MAbs did not inhibit CR4-dependent
rosettes.
The CR4-dependent rosettes formed with adherent mono-
cyte-derived macrophages were also inhibited by each of the
anti-p 150,95 MAbs (Table II). However, demonstration ofan-
tibody inhibition of rosetting required different assay condi-
tions than those used with monocytes or neutrophils. With
EC3bi bearing large amounts of fixed iC3b, 95-99% of adher-
ent monocyte-derived macrophages formed very avid rosettes
(frequently with > 40 EC3bi bound per cell), and anti-CR /
CR3 inhibition in the proportion of cells forming rosettes was
not apparent when rosettes were defined as cells bearing . 4
bound EC3bi. Subsequently, when the amount offixed iC3b/E
was greatly reduced and rosetting was carried out in isotonic
buffer, macrophages bore fewer bound EC3bi per cell and an-
tibody-mediated inhibition of rosetting could be more readily
demonstrated. Under these conditions, the EC3bi also did not
bind to CR1, so that anti-CR1 could be omitted from the inhi-
bition mixture. The three anti-p 150,95 MAbs had similar ro-
sette inhibiting capacity, and a mixture of the three MAbs
produced only slightly more inhibition than the individual
MAbs. As with neutrophils, substitution of anti-class I MAb
for anti-p 1 50,95 MAb did not inhibit CR4-dependent rosettes.
Because the anti-p150,95 MAbs produced only partial in-
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Table . Inhibition ofNeutrophil EC3bi Rosettes with Monoclonal Anti-p150,95
Inhibition of Inhibition of




Anti-CR1/CR3 + anti-Leu M5 14±2.3; P < 0.004 85 63
Anti-CR1 /CR3 + 3.9 12±2.9; P < 0.004 87 68
Anti-CR1/CR3 + L29 16±5.6; P < 0.004 83 58
Anti-CR1/CR3 + anti-Leu M5/3.9/L29 6±6.1; P < 0.001 94 84
Anti-CR1/CR3 + HB-120 anti-class I 40±12 55 0
Neutrophils in suspension
None 98±1.5
Anti-CR1 /CR3* 45±13§ 54
Anti-CR, I/CR3 + anti-Leu M5 40± 13; P > 0.5 59 11
Anti-CR1/CR3 + anti-Leu M5/3.9 35i10; P < 0.5 64 22
Anti-CR1/CR3 + anti-Leu M5/3.9/L29 14±6.2; P < 0.01 86 69
The results are derived from assays of four to eight neutrophil preparations. Mean values± 1 standard deviation are given, and P values compar-
ing rosette formation with anti-CR1/CR3 versus anti-CR1/CR3 plus anti-plO,95 were calculated by the Student's t test. * The following
amounts of antibodies were used: 140 Ag rabbit anti-CRI, 10 ,g anti-Mac-i, and 5 zg each of MN-41, anti-Mol, anti-Leu M5, 3.9, L29, and
HB- 120. Anti-CR I/CR3: mixture of rabbit anti-CRI, MN-4 1, anti-Mac-l, and anti-Mo-l. § This is the value for CR4-dependent rosette for-
mation used to calculate the values for inhibition of CR4 rosettes given in the third column.
hibition ofEC3bi rosettes, it appeared possible that none ofthe
MAbs were specific for the iC3b-binding site of pS50,95, and
that better inhibition ofp 150,95-dependent function might be
achieved by MAb-mediated modulation of p150,95. For this
purpose, experiments were carried out with macrophages on
which p150,95 had been modulated by cultivation on slides
coated with anti-p 150,95 (Table III). Partial, but significant
inhibition of EC3bi rosette formation was observed with cells
cultured on anti-plSO,95, and then nearly all of the remaining
rosettes were blocked by addition of fluid-phase anti-CR3.
This suggested that p150,95 could mediate EC3bi rosette for-
mation independently of CR3. When cells were cultured on
Table I. Inhibition ofAdherent Monocyte-derived Macrophage EC3bi Rosette Formation with Monoclonal Anti-p150,95
Inhibition of Inhibition of
Antibody treatment* EC3bi rosette formation all rosettes CR4 rosettes
None 89±7.5
MN-41 anti-CR3 48±6.8 46
Anti-Mol anti-CR3 50±7.8 44
Anti-Mac- I anti-CR3 60±12 33
MN-41 + Anti-Mol 45±15 49
MN-41 + Anti-Mol + Anti-Mac-I 36±8.7t 60
Anti-CR31 + Anti-Leu M5 18±8.8; P < 0.03 80 50
Anti-CR3 + 3.9 2 1±8.6; P < 0.05 76 42
Anti-CR3 + L29 19±9.1; P < 0.03 79 47
Anti-CR3 + Anti-Leu M5/3.9 18±9.1; P < 0.03 80 50
Anti-CR3 + Anti-Leu M5/3.9/L29 13±5.2; P < 0.004 85 64
Anti-CR3 + Anti-HB-120 (class I) 42±10 53 0
Assays were performed with EC3bi bearing 1.7 X 104 iC3b per E in isotonic HBSS/BSA; conditions that minimize EC3bi binding to CR1. The
results given are the mean values± 1 standard deviation for five preparations of monocyte-derived macrophages. In comparisons of rosette for-
mation with anti-CR3 versus anti-CR3 plus anti-p 150,95, P values were calculated by the Student's t test using the Tadpole program (Elsevier-
Biosoft, Cambridge, UK). * The amounts of antibody added were: 10 Mg anti-Mac-1, 5 ,g each of MN-41, anti-Mol, anti-Leu M5, 3.9, L29,
and HB- 120. Titrations of the individual anti-CR3 MAbs with each preparation of macrophages showed that the amounts used were 4- to 10-
fold greater than the amounts required to achieve maximum (plateau) values for inhibition of rosette formation (not shown). * This is the
baseline value for CR4-dependent rosette formation used to calculate the values for inhibition of CR4 rosettes given in the third column.
1Anti-CR3: mixture of MN-4 1, anti-Mac- 1, and anti-Mol.
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Table III. Blockade ofMacrophage CR4-dependent Rosette Formation by Cultivation of Cells on Surfaces Coated with Anti-plSO,95
Inhibition of Inhibition of
Antibody on culture surface Fluid-phase antibody added EC3bi rosette formation total rosettes CR4 rosettes
Mouse myeloma IgG None 86±8.6
Anti-CR3* 23±3.1 73
Anti-CR3 + Anti-p150,95§ 9.3±3.4; P < 0.002 83 60
MAb 3.9 anti-p150,95 None 59± 15; P < 0.02 31
Anti-CR3 2.8± 1.6; P < 0.001 97 88
MN-41 anti-CR3 None 24±2.8 72
Anti-p150,95 6.3±4.1 93 73
HB-120 anti-class I None 88±7.5 0
Anti-CR3 25±4.1 65
Anti-CR3 + Anti-p150,95 9.3±0.9 83 60
The results given are the mean values± 1 standard deviation from five preparations of nonadherently cultured monocyte-derived macrophages.
Inhibition of rosette formation on MAb 3.9 coated surfaces versus nonspecific myeloma IgG-coated surfaces (31 %) was statistically significant.
Modulation on surfaces coated with MAb 3.9 anti-p 150,95 versus modulation on either myeloma IgG or anti-class I coated surfaces allowed
significantly more inhibition of rosette formation by fluid phase anti-CR3 (P value for comparison between MAb 3.9 versus P1.17 myeloma
IgG surface is given). P values were calculated as in Table II. * Mixture of three anti-CR3 MAbs: MN-41, anti-Mac-l, and anti-Mol; same
amounts shown in Table II to produce plateau values for inhibition of rosette formation. By definition, this is the control level of CR4-de-
pendent rosette formation; i.e., the level of EC3bi rosettes in the presence of anti-CR3. The inhibition of CR4-dependent rosette formation cal-
culated in the fourth column is based on this value. § Mixture ofthree anti-pl50,95 MAbs: 3.9, anti-Leu MS, and L29, 5 ig of each.
control surfaces coated with myeloma IgG or HB- 120 anti-
class I instead ofMAb anti-p 150,95, a comparable blockade of
rosettes required fluid phase anti-p 1 50,95 in addition to fluid
phase anti-CR3. Another important finding was that modula-
tion on a surface coated with anti-CR3 MAb produced recipro-
cal results to those obtained with MAb anti-p 150,95 coated
surfaces. Surface modulation with a single MAb anti-CR3 was
as effective in blocking EC3bi rosettes as was the addition of
three fluid phase anti-CR3 MAbs to cells on myeloma IgG or
anti-class I coated surfaces. The majority of the remaining
CR&-dependent rosettes expressed after CR3 modulation were
blocked by further addition of fluid phase anti-p 1 50,95 MAbs.
To exclude the possibility that rosette inhibition might be
have been produced by the MAb-triggered release of proteo-
lytic enzymes that converted EC3bi to unreactive EC3d, su-
pernatants of rosette inhibition mixtures of neutrophils or
macrophages were incubated with EC3bi for 1 h at 37°C.
Analysis with '25I-labeled anti-C3c MAb showed no loss ofC3c
antigens from these EC3bi as compared to control EC3bi in-
cubated in parallel in HBSS/BSA buffer.
Absence of CR4-dependent rosettes with neutrophils and
monocyte-derived macrophagesfrom a patient with partial de-
ficiency ofthe LFA-J/CR3/pJ50,95 membrane antigenfamily.
Normal neutrophils, tested in parallel with the patient's neu-
trophils, formed 23% CR4-dependent EC3bi rosettes that were
reduced to 8 and 2% by anti-Leu M5 and 3.9, respectively
(Table IV). The patient's neutrophils did not express CR4 ac-
tivity, because all of the EC3bi rosettes formed in low-ionic
strength BDVA buffer were blocked by the anti-CRI/CR3
mixture. Tests of this patient's neutrophils revealed 6,300 CR3
per neutrophil (- 10% of normal) by assays for uptake of
1251I-anti-CR3, whereas no expression of p1 50,95 antigens was
observed (data not shown).
Monocytes from the patient and a normal control were
analyzed after being cultured nonadherently for 7 d. As found
before (Table III), the CR4 rosetting activity ofthe normal cells
was inhibited by anti-p 1 50,95 present on surfaces onto which
nonadherently grown monocytes were allowed to attach
(Table IV). By contrast, no EC3bi rosettes were observed when
the patient's monocytes were examined under the same assay
conditions that generated 99% EC3bi rosette formation with
the normal monocyte control (Table IV).
Comparison ofthe amounts ofCR,, CR3, and p150,95 on
neutrophils, monocytes, and macrophages. The relative CR4
dependence of EC3bi rosette formation appeared to correlate
with the level of surface p1 50,95 versus the levels of CR1 and
CR3 (Table V). Neutrophils and monocytes expressed 3-12
times more CR1 and CR3 than p150,95, whereas monocyte-de-
rived macrophages expressed increased amounts of p150,95
that approached levels ofCRI and CR3.
Comparison of isolated monocytes with tissue macro-
phages by immunoperoxidase staining demonstrated that tis-
sue macrophages from eight organs exhibited abundant stain-
ing for p150,95 in combination with weak or absent staining
for CR1 and CR3 (Table VI). Figs. 2-4 illustrate the indirect
immnunohistochemical staining patterns obtained on a variety
of tissues using MAbs E 11 (CR1), 44 (CR3), and 3.9 (p 150,95).
In Fig. 2, the p150,95-positive labeling of tissue macrophages
in thymic medulla (Fig. 2 a) and spleen white pulp (Fig. 2 d) is
compared with the lack of staining for CR1 and CR3 on the
same cells (Fig. 2 b, c, e, f). Strong expression of CRI was
evident in lymphoid tissues, but it was restricted to lympho-
cytes (probably B cells, Fig. 2f) and dendritic reticulum cells.
CR3 was also readily detectable on tissue granulocytes (poly-
morphonuclear cells, Fig. 2 e). In Fig. 3, the p150,95 express-
ing spleen white pulp macrophages (Fig. 3 a) are compared to
the CR3-positive granulocytes found within the spleen mar-
ginal zone (Fig. 3 b). Another comparable situation was seen in
the tonsil where p150,95 expressing macrophages were found
in interfollicular areas (Fig. 3 c) and germinal centers (Fig. 3, c,
e), whereas CR3-expressing granulocytes were seen in blood
vessels (Fig. 3, d: see arrow), or in situations of inflammation
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Table IV. Absence ofCR4 Rosette Formation with Neutrophils and Monocyte-derived Macrophages
from a Patient with Partial Deficiency ofLFA-J/CR3/plSO,95 (CD18)
EC3bi rosette formation
Cell type Fluid-phase antibody addition Normal control CD 18 deficient patient
Adherent neutrophils (BDVA) None 98 81
Anti-CR, 99 45
Anti-CR, /CR3* 23* 0
Antii-CR/CR3 + anti-Leu M5 8 Not done
Anti-CRI/CR3 + MAb 3.9 2 Not done
Teflon 7-d cultured macrophages (HBSS/BSA)
Tested on myeloma IgG surface None 99 0
Anti-CR3 52 0
Tested on MAb 3.9 surface None 47 0
Anti-CR3 4 0
* Anti-CR1 /CR3: mixture of rabbit anti-CR1, MN-4 1, anti-Mac- 1, and anti-Mol. With the Teflon-cultured macrophages, EC3bi with reduced
amounts of fixed iC3b in isotonic HBSS/BSA were used as in the experiments shown in Table III so that anti-CR1 was not required and only
the anti-CR3 mixture of three MAbs was used. $ By definition, this is the control level of CR4-dependent rosette formation.
where they were found in large numbers in the tonsil, particu-
larly in the trabecular areas. The general tissue macrophage
pattern of strong expression of pl 50,95 compared to CR3 is in
contrast to the expression of these molecules by monocytes
and neutrophils which exhibited only moderate expression of
p150,95 (Fig. 3 f) compared to CR3 (Fig. 3 g). Various tissues
that contained p1 50,95-expressing macrophages are illustrated
in Fig. 4. Both alveolar macrophages and skin macrophages
expressed CR3 at much lower levels than p150,95. Although
macrophages from bronchus stained predominantly for CR3
rather than for p150,95, additional staining for CD14 sug-
gested that these were probably immature cells (38) despite
their large size (data not shown).
Discussion
The current study showed that membrane surface p150,95
expressed the same type of iC3b-receptor activity that had
been previously demonstrated with the detergent-solubilized
Table V. Quantitation ofCR,, CR3, and CR4
on Neutrophils, Freshly Isolated Monocytes,
and Monocyte-derived Macrophages (M4)
Molecules/cell determined by uptake
of 1251-mAbs*
CR, CR3 CR4
Neutrophils 41,772+6,552 57,496±12,428 5,941±363
Monocytest 25,365±8,954 24,097±14,836 7,747±5,898
Adherently
cultured Mot 36,458±29,330 126,796±60,924 63,095±24,935
* Mean numbers± 1 SD are given for four different preparations ofeach cell type.
$ Monocytes were assayed within 2 h of adherence.
I Adherently cultured MO were generated from the same preparations of
monocytes by culture for 7 d in 24-well plastic plates. Many of these cells are
much larger than monocytes, so that the receptor number increase reflects both
an increase in cell size as well as a probable increase in receptor density per
unit area of membrane.
molecule (22). This iC3b-receptor activity of pl 50,95 is proba-
bly identical to the neutrophil receptor.for EC3bi and EC3dg
rosettes that had been previously designated CR4 (23). Because
neutrophils and monocytes express the iC3b-receptors CRI
and CR3 in addition to CR4, demonstration of p150,95 (CR4)
dependent EC3bi rosette formation required prior blockade of
CR1 and CR3 with a polyclonal mixture of antibodies to CRI
and CR3 . Under these conditions, EC3bi rosettes were blocked
by each of three MAbs directed to unique epitopes on the
a-chain ofplSO,95. Neutrophils and monocytes that expressed
very small amounts of p150,95 exhibited only low levels of
CR4-dependent rosette formation, the detection of which re-
quired large amounts of fixed iC3b and low-ionic strength
buffer. By contrast, culture-derived macrophages expressed
greatly increased amounts ofpl 50,95 and avid CR4-dependent
rosette formation that was readily detectable with small
amounts of fixed iC3b and isotonic buffer. Normal neutrophil
and macrophage CR4-dependent rosettes were inhibited by
anti-p 150,95, whereas neutrophils and macrophages from a
patient with inherited deficiency of the entire LFA- I/CR3/
p150,95 membrane antigen family failed to form CR4-depen-
dent rosettes.
Table VI. Immunoperoxidase Staining ofCR,, CR3,
and p150,95 on Monocytes versus Tissue Macrophages
Relative intensity of staining
MAb El 1
Cell type or source (CR1) MAb 44 (CR3) MAb 3.9 (p150,95)
Blood monocytes Moderate Strong Very weak
Alveolar macrophages Negative-weak Weak-moderate Moderate
Brain macrophages Negative Negative Moderate
Bronchus macrophages Weak Strong Negative
Colon macrophages Negative Negative Moderate
Skin macrophages Negative Weak Moderate
Splenic macrophages Weak Weak Strong
Thymus macrophages Negative Negative Strong
Tonsil macrophages Negative Negative Strong
iC3b-Receptor (CR4) Activity ofp150,95 645
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Figure 2. Immunoperoxidase labeling of thymus and spleen with
mAbs specific for CR1, CR3, and p 150,95. Sections of thymus me-
dulla labeled with: (a) MAb 3.9 (p150,95) showing many reactive
macrophages, versus sections (b) MAb 44 (CR3), (c) MAb EII (CR1)
showing little positive staining; magnification, 680. Consecutive sec-
tions of spleen white pulp labeled with: (d) MAb 3.9 illustrating ag-
gregations of macrophages within the white pulp; area labeled with
star below the arteriole (a); (e) MAb 44 showing chiefly positive gran-
ulocyte labeling in the marginal zone area at the edge of the white
pulp (see star), (f) MAb E II showing strong staining of lymphocytes
(B cells) within an active germinal center adjacent to the arteriole
(see star above arteriole); magnification 680.
The p150,95 molecule was originally discovered by immu-
noprecipitation with MAbs to the common d-subunit of the
LFA- I/Mac- 1 family (1). Tests of its function were not possi-
ble until MAbs to its unique a subunit were generated (2, 3,
31), and these studies were complicated by similar functions
expressed by CR3 on the same cell. Evidence that p150,95
functions along with CR3 and LEA- I in promoting neutrophil
adherence to protein-coated glass surfaces was obtained by
examining both MAb-treated normal neutrophils and neutro-
phils from patients with an inherited deficiency of the entire
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Figure 3. Immunoperoxidase labeling of monocytes, spleen, and ton-
sil with MAbs specific for CR3 and p1 50,95. Sections of spleen la-
beled with: (a) MAb 3.9 (p150,95) showing macrophage staining in
the white pulp (wp) area and in the surrounding marginal zone (open
arrow) and red pulp; (b) MAb 44 (CR3) showing strong staining of
granulocytes in the marginal zone (open arrow) and red pulp; magni-
fication, 270. Sections of tonsil labeled with: (c) MAb 3.9 showing
extensive labeling of interfollicular and germinal center macro-
phages, and (d) MAb 44 showing labeling of a few granulocytes
within a blood vessel (open arrow); magnification 440. In sections c
and d, the border of the germinal center is indicated by two opposing
arrows. Section e shows higher magnification (1,090) of tonsil ger-
minal center macrophages with branched processes stained with
MAb 3.9. Peripheral blood monocytes (small open arrow) and neu-
trophils (large open arrow) labeled with: (f) MAb 3.9 and (g) MAb
44. Two eosinophils, positively stained because of endogenous perox-
idase activity are labeled e in the cell center and are seen at the left
border of section (f) and the right border of section (g); magnifica-
tion 1,090.


































dermis at interface with epidermis (open arrow); 680 magnification;
(c) lung, showing a cluster of p 1 50,95 positive alveolar macrophages,
1,090 magnification; (d) brain, showing a p150,95 positive microglial
cell; 680 magnification.
phils and monocytes, a mixture of three MAbs to CR3 was
combined with polyclonal anti-CR, to block all CR1- and
CR3-dependent rosette formation with EC3bi. This was essen-
tial with neutrophils that expressed 10 times more ofboth CR1
and CR3 than p150,95. Second, culture-derived macrophages
were examined because previous studies had demonstrated
that these cells expressed very avid receptors for EC3bi that
were only poorly inhibited by mixtures of anti-CR1 and anti-
CR3 (26). With both neutrophils and macrophages, CR4-de-
pendent resetting was blocked by anti-p 150,95. The data sug-
gested that p1 50,95 might be a major iC3b-receptor on macro-
phages because modulation of p150,95 with a single MAb
produced significant inhibition of EC3bi rosette formation
without additional blockade of CR1 and CR3.
It should be noted that the pI 50,95/CR4 molecule may be
different from the neutrophil/platelet receptor for fluid-phase
C3dg-dimers that has recently also been called CR4 (40). Al-
though the p150,95 molecule may bind to fixed C3dg in addi-
Figure 4. Immunoperoxidase labeling of spleen, lung, skin, and brain
with MAb 3.9 (p150,95). Tissue section of(a) spleen, showing mac-
rophages adjacent to arteriole in white pulp at higher magnification
(680); (b) skin, showing positively stained macrophages within
LFA-1/CR3/pl50,95 family (12). Similar types of antibody
blocking experiments have also indicated that p150,95 may be
involved in conjugate formation between cytotoxic T cells and
their sensitive target cells (15).
Evidence that p150,95 might be a complement receptor
has come from several sources. First, monocyte rosetting with
EC3d was inhibited by modulation with anti-#-chain but not
by modulation with anti-CR3 or anti-LFA-l (39). Second, an
iC3b/C3dg receptor activity (CR4) was demonstrated on neu-
trophils that was not inhibited by anti-CR, and anti-CR3, and
which was absent on neutrophils from patients with inherited
deficiency of the LFA-l/CR3/plS0,95 (23). Third, detergent-
solubilized p150,95 from U937 cells was shown to bind and
elute from iC3b-Sepharose after selective removal of CR3 by
immunoprecipitation (22).
Because of two previous failures to demonstrate anti-
p150,95 inhibitable EC3bi rosettes (2, 22), two different ap-
proaches were adopted in the current study. First, with neutro-
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tion to fixed iC3b (23), our current data with rosetting as well
as published data with the isolated molecule indicate that
p150,95 binding to iC3b is completely inhibited by EDTA. In
contrast, the binding of '25I-C3dg-dimers to neutrophils was
unaffected by EDTA (41). Moreover, p150,95 antigens and
CR4-dependent EC3bi rosetting activity are expressed on both
monocytes and neutrophils, but are undetectable on platelets
(14, 42). In contrast, the C3dg-dimer receptor is present on
platelets and absent from monocytes (40).
The possible specificity of CR4 for fixed C3dg was not
investigated in the present study because of the difficulty in
obtaining EC3dg that were totally free of fixed iC3b. EC3dg
usually bear 5-10% contamination with fixed iC3b detectable
with 1251I-monoclonal anti-C3c (17). If such EC3dg form ro-
settes that are not inhibitable by mixtures of anti-CR, and
anti-CR3 (23), then it can not be excluded that such CR4-de-
pendent rosettes might be due to this small amount of fixed
iC3b. Quantitatively, however, such 10% contamination with
iC3b would amount to < 6,000 iC3b molecules on EC3dg
bearing 60,000 total fixed iC3b/C3dg molecules, and EC3bi
specifically prepared with this amount of fixed iC3b did not
form neutrophil CR4-dependent rosettes (23). Although C3dg
can be obtained free of iC3b in the fluid-phase, available data
suggests that the C3dg-dimers or C3dg-coated microspheres
generated from such pure C3dg probably do not bind to CR4,
as their uptake by neutrophils is unaffected by EDTA (17, 41).
It is thus likely that the analysis of CR4 binding of C3dg will
require indicator particles bearing only C3dg fixed via its phys-
iologic ester bond site.
The data presented here and in previous reports (14, 31,
43, 44) support the concept that monocytes undergo a switch
in C3-receptor types from CRI and CR3 (Mac-l) to CR4
(pl50,95) during differentiation into macrophages. Quantita-
tion of surface antigens with '25I-MAbs showed that culture-
derived macrophages expressed eight times more CR4 than
freshly isolated monocytes. Although this greatly facilitated
tests of the p 150,95 relationship to CR4, the data suggests that
the differentiation ofC receptor phenotypes produced in vitro
is different from that of normal resting macrophages because
CRI and CR3 were also increased on the culture-derived mac-
rophages. When tissue macrophages from several organs were
examined by immunoperoxidase staining, the majority of
macrophages stained for CR4 (p150,95) and failed to stain for
CR1 and CR3. Normally there was little CR3 on tissue macro-
phages in combination with strong expression of CR4. Much
larger amounts of CR3 have been observed in inflammatory
tissues containing granulocyte and monocyte infiltrates, such
as those frequently seen in synovial tissues from patients with
rheumatoid arthritis (45).
Preliminary findings further suggest that CR4 can acquire
the ability to induce ingestion of EC3bi in a manner similar to
CR3. Adherent culture-derived macrophages ingested EC3bi
after blockade of CR1 and CR3, and then this CR4 dependent
ingestion was inhibited by anti-p 150,95. Others have also re-
ported that p 150,95 (as well as CR3 and LFA- 1) could mediate
phagocytosis of unopsonized bacteria and yeast (46, 47).
IfCR4 is primarily expressed and functional on tissue mac-
rophages rather than on blood phagocytes, then characteriza-
tion of its activity will be more difficult than previous func-
tional studies ofCR1 and CR3. It will be particularly important
to determine whether CR4 mediates clearance of iC3b-coated
complexes in the liver. Studies in both humans and monkeys
infused with C3-coated red blood cells or immune complexes
have demonstrated a major role for fixed C3 in clearance by
the liver (48, 49). Fixed iC3b, rather than fixed C3b, is proba-
bly the most prevalent opsonic C3 fragment on immune com-
plexes and bacteria in the blood. Thus, the current data show-
ing the function ofCR4 as an iC3b-receptor and its preferential
expression on tissue macrophages suggest that CR4 may be an
important receptor involved in C3-mediated clearance. Pre-
liminary studies of liver sections by immunoperoxidase stain-
ing and of isolated Kupffer cells by assay for uptake of '25I-la-
beled MAbs have indicated that Kupffer cells express more
CR4 than either CR1 or CR3 (Ross, G. D., M. J. Walport, and
N. Hogg, unpublished observation).
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